Bicara Therapeutics (BCAX)

Profile

Full Name

Bicara Therapeutics Inc.

Ticker Symbol

BCAX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

Indexes

Not included

Website

http://www.bicara.com

Employees

55

Key Details

Price

$13.27

Market Cap

$610.76M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$0.36(-198.76% YoY)

PE Ratio

-

Next earnings date

May 30, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$13.27
BCAX price is $13.27

Price All-time High

$27.07
BCAX price is currently -50.98% below its historical high of $27.07

Price Today Change

+1.84%
BCAX price is up +1.84% today

Price YTD Change

-23.82%
BCAX price is down -23.82% since January 1st

Price 1-year Change

-
BCAX price 1-year change is unknown

Price 3-year Change

-
BCAX price 3-year change is unknown

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market Cap

$610.76M
BCAX market capitalization is $610.76 million

Market Cap 3-year Change

-
BCAX market capitalization 3-year change is unknown

Market Cap All-time High

$1.25B
BCAX market capitalization is currently -50.98% below its historical high of $1.25 billion

Market Cap Sector Rank

71.32%
BCAX market capitalization is higher than 71.32% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-
BCAX shares outstanding 1-year change is unknown

Shares Outstanding 3-Year Change

-
BCAX shares outstanding 3-year change is unknown

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.20
BCAX beta is 1.20

200-day SMA

$17.90
BCAX price is currently -25.87% below its 200-day simple moving average

50-day SMA

$13.03
BCAX price is currently +1.83% above its 50-day simple moving average

RSI

47.37
BCAX 14-day relative strength index is 47.37

Volume

1.02
BCAX 30-day relative volume is 1.02

ATR

$1.25
BCAX average true range is $1.25

10-day Historical Volatility

65.96%
BCAX 10-day historical volatility is 65.96%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
BCAX annual revenue value is unknown

Revenue Analysts Estimate

-
BCAX annual revenue consensus analysts' forecast is unknown

Revenue 1-year Change

-
BCAX annual revenue 1-year change is unknown

Revenue Sector Rank

-
BCAX annual revenue is unknown

EPS

EPS

-$0.36
BCAX annual earnings per share is -$0.36

EPS Analysts Estimate

-$2.64
BCAX annual earnings per share is currently -86.38% lower than the consensus analysts' forecast

EPS 1-year Change

-198.76%
BCAX annual earnings per share is down -198.76% year-on-year

EPS Sector Rank

72.53%
BCAX annual earnings per share is higher than 72.53% of companies in Healthcare sector

Profit

Gross Profit

-
BCAX annual gross profit value is unknown

Gross Margin

-
BCAX annual gross profit margin value is unknown

Operating Profit

-$39.89M
BCAX annual operating income is -$39.89 million

Operating Margin

-
BCAX annual operating profit margin value is unknown

Net Income

-$51.98M
BCAX annual net profit is -$51.98 million

Net Margin

-
BCAX annual net profit margin value is unknown

Expenses

Total Expenses

$39.89M
BCAX annual total expenses is $39.89 million

Operating Expenses

$39.89M
BCAX annual total operating expenses is $39.89 million

Cost Of Goods Sold

-
BCAX annual cost of goods sold value is unknown

Selling, General & Administrative Expenses

$9.27M
BCAX annual SGA is $9.27 million

Depreciation And Amortization

$19.00K
BCAX annual depreciation & amortization is $19.00 thousand

Interest Expense

$0.00
BCAX annual interest expense is $0.00

Income Tax

$5000.00
BCAX annual income tax is $5000.00

EBIT & EBITDA

EBIT

-$51.98M
BCAX annual earnings before interest & taxes is -$51.98 million

EBITDA

-$51.96M
BCAX annual EBITDA is -$51.96 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total Assets

$233.98M
BCAX annual total assets is $233.98 million

Non Current Assets

$2.91M
BCAX annual long term assets is $2.91 million

Current Assets

$231.07M
BCAX annual total current assets is $231.07 million

Cash And Cash Equivalents

$230.44M
BCAX annual cash & cash equivalents is $230.44 million

Accounts Receivable

-
BCAX annual accounts receivable value is unknown

Inventory

-
BCAX annual inventory value is unknown

Liabilities

Total Liabilities

$382.75M
BCAX annual total liabilities is $382.75 million

Long Term Liabilities

$367.67M
BCAX annual total long term liabilities is $367.67 million

Current Liabilities

$15.09M
BCAX annual total current liabilities is $15.09 million

Accounts Payable

$3.19M
BCAX annual accounts payable is $3.19 million

Debt

Total Debt

$657.00K
BCAX annual total debt is $657.00 thousand

Total Debt 1-year Change

+100%
BCAX annual total debt is up +100% year-on-year

Long Term Debt

$372.00K
BCAX annual long term debt is $372.00 thousand

Short Term Debt

$285.00K
BCAX annual short term debt is $285.00 thousand

Equity & Capital

Shareholders Equity

-$148.77M
BCAX annual stockholders equity is -$148.77 million

Book Value

-$148.77M
BCAX annual book value is -$148.77 million

Retained Earnings

-$153.02M
BCAX annual retained earnings is -$153.02 million

Working Capital

$215.99M
BCAX annual working capital is $215.99 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash From Operations

-$45.63M
BCAX annual cash flow from operations is -$45.63 million

Cash From Operations 1-year Change

-42.25%
BCAX annual cash flow from operations is down -42.25% year-on-year

Cash From Investing

-$586.00K
BCAX annual cash flow from investing activities is -$586.00 thousand

Cash From Investing 1-year Change

-205.21%
BCAX annual cash flow from investing activities is down -205.21% year-on-year

Cash From Financing

$272.50M
BCAX annual cash flow from financing activities is $272.50 million

Cash From Financing 1-year Change

+759.74%
BCAX annual cash flow from financing activities is up +759.74% year-on-year

CAPEX

CAPEX

-
BCAX annual capital expenditures value is unknown

CAPEX 1-year Change

-
BCAX annual capital expenditures 1-year change is unknown

Free Cash Flow

Free Cash Flow

-$46.21M
BCAX annual free cash flow is -$46.21 million

Free Cash Flow 1-year Change

-43.22%
BCAX annual free cash flow is down -43.22% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross Margin

-
BCAX annual gross profit margin value is unknown

Operating Margin

-
BCAX annual operating profit margin value is unknown

Net Margin

-
BCAX annual net profit margin value is unknown

ROA & ROE

ROA

-22.22%
BCAX annual return on assets is -22.22%

ROE

34.94%
BCAX annual return on equity is 34.94%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
BCAX price to earnings ratio value is unknown

PE Ratio Sector Rank

-
BCAX price to earnings ratio is unknown

PB Ratio

PB Ratio

1.20
BCAX price to book ratio is 1.20

PB Ratio Sector Rank

48.3%
BCAX price to book ratio is higher than 48.3% of companies in Healthcare sector

PS Ratio

PS Ratio

-
BCAX price to sales ratio value is unknown

PS Ratio Sector Rank

-
BCAX price to sales ratio is unknown

Enterprise value

Enterprise Value

$90.45M
BCAX enterprise value is $90.45 million

Enterprise Value Sector Rank

47.92%
BCAX enterprise value is higher than 47.92% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-4.39
BCAX EV/EBITDA is -4.39

EV/EBITDA Sector Rank

21.54%
BCAX EV/EBITDA is higher than 21.54% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current Ratio

15.32
BCAX annual current ratio is 15.32

Quick Ratio

-
BCAX annual quick ratio value is unknown

Leverage

Debt To Equity

0.00
BCAX annual debt to equity ratio is 0.00

Interest Coverage Ratio

-
BCAX annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
BCAX piotroski f-score value is unknown

Altman Z-Score

-
BCAX altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Mar 13, 25 Cantor Fitzgerald
Overweight
Feb 12, 25 Wedbush
Outperform
Feb 6, 25 Wedbush
Outperform
Jan 27, 25 HC Wainwright & Co.
Buy
Dec 6, 24 HC Wainwright & Co.
Buy
Oct 8, 24 TD Cowen
Buy
Oct 8, 24 Stifel
Buy
Oct 8, 24 Morgan Stanley
Overweight
Oct 8, 24 Cantor Fitzgerald
Overweight

Institutional Ownership

Similar stocks

IMNM logo
Immunome (IMNM)
KIDS logo
OrthoPediatrics (KIDS)
TRVI logo
Trevi Therapeutics (TRVI)
KALV logo
KalVista Pharmaceuticals (KALV)
NUVB logo
Nuvation Bio (NUVB)
SIBN logo
SI-BONE (SIBN)
BVS logo
Bioventus (BVS)
OnKure Therapeutics (OKUR)
BCYC logo
Bicycle Therapeutics (BCYC)
  • What is the ticker symbol for Bicara Therapeutics?
  • Does Bicara Therapeutics pay dividends?
  • What sector is Bicara Therapeutics in?
  • What industry is Bicara Therapeutics in?
  • What country is Bicara Therapeutics based in?
  • Is Bicara Therapeutics in the S&P 500?
  • Is Bicara Therapeutics in the NASDAQ 100?
  • Is Bicara Therapeutics in the Dow Jones?
  • When was Bicara Therapeutics's last earnings report?
  • When does Bicara Therapeutics report earnings?
  • Should I buy Bicara Therapeutics stock now?

What is the ticker symbol for Bicara Therapeutics?

The ticker symbol for Bicara Therapeutics is NASDAQ:BCAX

Does Bicara Therapeutics pay dividends?

No, Bicara Therapeutics does not pay dividends

What sector is Bicara Therapeutics in?

Bicara Therapeutics is in the Healthcare sector

What industry is Bicara Therapeutics in?

Bicara Therapeutics is in the Biotechnology industry

What country is Bicara Therapeutics based in?

Bicara Therapeutics is headquartered in United States

Is Bicara Therapeutics in the S&P 500?

No, Bicara Therapeutics is not included in the S&P 500 index

Is Bicara Therapeutics in the NASDAQ 100?

No, Bicara Therapeutics is not included in the NASDAQ 100 index

Is Bicara Therapeutics in the Dow Jones?

No, Bicara Therapeutics is not included in the Dow Jones index

When was Bicara Therapeutics's last earnings report?

Bicara Therapeutics's most recent earnings report was on Mar 27, 2025

When does Bicara Therapeutics report earnings?

The next expected earnings date for Bicara Therapeutics is May 30, 2025

Should I buy Bicara Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page